ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0009

Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis

Xiaodong Wang, Mark Matijevic, Allen Poma, Shauna Quinn, Minggeng Gao, Lisa Crockett, Jessica Karnes, Keith Wilcoxen and Hua Mu, Zenas BioPharma, Waltham

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, B-Cell Targets, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across multiple autoimmune disorders. The purpose of this investigation was to evaluate the pharmacokinetics (PK), receptor occupancy (RO), and pharmacodynamics (PD) of obexelimab following intravenous (IV) administration in adult healthy volunteers and in patients with rheumatoid arthritis (RA).

Methods: The PK of obexelimab in healthy volunteers was investigated in a Phase 1, single center, randomized, partially double-blinded, placebo-controlled, single ascending dose (SAD) study. Forty-eight subjects were randomized (3:1) to receive single IV infusions of obexelimab (0.03, 0.1, 0.2, 0.6, 2.0, 5.0, and 10.0 mg/kg) or placebo. Serial blood samples were obtained to at least Day 71 after dosing for determination of serum PK, CD19/FcγRIIb RO, and CD20+ B cell counts.

The PK of obexelimab in RA patients was investigated in a Phase 2a, multi-center, randomized, double-blinded, placebo-controlled study of multiple ascending dose (MAD) (Part A) followed by a cohort expansion (Part B). A total of 57 RA patients were randomized (3:1) to receive ascending IV infusions of obexelimab (0.3, 1.0, 3.0 and 10.0 mg/kg) or placebo every two weeks (Q2W) for 6 doses (Part A), followed by an expansion cohort at 10.0 mg/kg or placebo (randomized 2:1) Q2W for 6 doses (Part B). Serial blood samples were obtained after the first and last (6th) dose and to Day 169 for determination of serum PK, CD19 RO, and CD20+ B cell counts.

PK parameters were estimated by non-compartmental analysis. CD19 RO, FcγRIIb RO, and CD20+ B cell counts were determined via flow cytometry.

Results: Obexelimab demonstrated similar PK profiles in healthy volunteers and RA patients. Dose proportional PK was observed in both studies.

In the SAD study, faster clearance and shorter half-life was observed at lower dose levels (0.03 to 0.2 mg/kg). At the 4 higher doses (0.6 to 10.0 mg/kg), clearance and half-life were relatively constant (averaged 16.7 ± 3.4 mL/day/kg and 3.6 ± 1.2 days, respectively), consistent with target-mediated drug disposition.

In the MAD study, clearance and half-life were similar across all 4 dose levels and comparable to those from the SAD study. The last dose clearance and half-life averaged 15.2 ± 3.7 mL/day/kg and 3.5 ± 1.1 days, respectively.

In the SAD study, complete CD19 RO was demonstrated on Day 2 at all dose levels. FcγRIIb RO was partially saturated (< 45%) at lower doses up to 2 mg/kg and higher saturation (~70 to 80%) was achieved with 5 and 10 mg/kg doses. Similarly in the MAD study, complete CD19 RO was demonstrated from Day 2 through the end of dosing for the 1.0 to 10.0 mg/kg cohorts. In both studies, the nadir of CD20+ B cells was observed at approximately 50% of baseline values. Recovery of CD19/FcγRIIb RO and CD20+ B cells to 80% of baseline values appeared to be dose dependent.

Conclusion: Obexelimab PK were similar between adult healthy volunteers and RA patients. Robust RO and PD data at the investigated doses from both studies supported further clinical development of obexelimab to treat B-cell mediated autoimmune diseases.


Disclosures: X. Wang, Zenas BioPharma; M. Matijevic, Zenas Biopharma; A. Poma, Zenas BioPharma; S. Quinn, Zenas BioPharma; M. Gao, Zenas Biopharma; L. Crockett, Zenas BioPharma; J. Karnes, Zenas BioPharma; K. Wilcoxen, Zenas BioPharma; H. Mu, Zenas Biopharma.

To cite this abstract in AMA style:

Wang X, Matijevic M, Poma A, Quinn S, Gao M, Crockett L, Karnes J, Wilcoxen K, Mu H. Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/pharmacokinetics-receptor-occupancy-and-pharmacodynamics-of-obexelimab-following-intravenous-administration-in-adult-healthy-volunteers-and-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacokinetics-receptor-occupancy-and-pharmacodynamics-of-obexelimab-following-intravenous-administration-in-adult-healthy-volunteers-and-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology